[\/et_pb_cta][et_pb_toggle title=\"Hearing Health Foundation | Emerging Research Grants \" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" hover_enabled=\"0\" global_colors_info=\"{}\" sticky_enabled=\"0\"]<\/p>\n
Hearing Health Foundation invites proposals for the following awards within its Emerging Research Grants program:<\/p>\n
- \n
- Elizabeth M. Keithley, Ph.D. Early Stage Investigator Awards (any topic<\/u>)\u00a0<\/li>\n
- \n
- $50,000 p.a. for two years, up to a total of $100,000<\/li>\n<\/ul>\n<\/ul>\n
- \n
- Focused Discovery Awards\u00a0for\u00a0<\/span>Age-related hearing loss<\/u>,\u00a0<\/span>M\u00e9ni\u00e8re's\u00a0d<\/span>isease<\/u>,<\/span>\u00a0Pain and\/or loudness hyperacusis<\/u>, and\u00a0<\/span>Tinnitus<\/u><\/li>\n
- \n
- $50,000 p.a. for two years, up to a total of $100,000<\/li>\n<\/ul>\n<\/ul>\n
- \n
- Expanded Discovery Awards\u00a0for\u00a0Central Auditory Processing Disorder<\/u><\/span>\u00a0<\/span><\/li>\n
- \n
- $100,000 p.a. for two years, up to a total of $200,000<\/li>\n<\/ul>\n<\/ul>\n
LOIs are due\u00a0December 5<\/strong>.\u00a0<\/p>\n
Please see the full RfP, instructions, and the ERG Policy at hhf.org\/how-to-apply<\/span><\/a>.\u00a0<\/p>\n
Select applicants will be invited in January to submit full proposals, which will be due April 6.\u00a0<\/p>\n
The project year (1) starts October 1, 2026.<\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\"Usher Syndrome Society | Translational Research Grant\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" global_colors_info=\"{}\"]<\/p>\n
Important Dates:<\/strong><\/p>\n
Applications Due: October 24, 2025
Notification of Award: December 15, 2025
Funds Available: January 1, 2026<\/p>\nBackground:<\/strong><\/p>\n
The Usher Syndrome Society (USS) is a non-profit organization whose
mission is to raise public awareness and research funds for every type of Usher syndrome,
to find treatments and ultimately a cure for Usher syndrome (USH). USS has secured
commitments to fund another round of USS Translational Research Grants.<\/p>\nFor full Application instructions, CLICK HERE!<\/a><\/strong><\/span><\/p>\n
For more information, see: https:\/\/www.ushersyndromesociety.org\/<\/a><\/span><\/p>\n
<\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\"2025 Grant Opportunity- Tinnitus Quest\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" global_colors_info=\"{}\"]<\/p>\n
Tinnitus Quest is proud to open up for its first round of research funding! We welcome applications from qualified researchers with fresh ideas on how to silence tinnitus. We offer two types of grants:<\/p>\n
- \n
- Two smaller research grants for postdoctoral fellows, staff scientists, and independent investigators with a total budget not to exceed USD $100,000<\/li>\n
- One larger research grant for independent investigators with a total budget not to exceed USD $200,000<\/li>\n<\/ul>\n
Interested applicants are invited to read our full\u00a0<\/span>Request for Proposals (RFP) document<\/a><\/span> to understand more about eligibility, scientific focus, the grant review process, and award conditions.<\/p>\n
Click HERE<\/a><\/span> to apply.<\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\"NIDCD - Dissemination and Implementation Research in Communication Disorders Conference (U13 Clinical Trial Not Allowed)\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" global_colors_info=\"{}\"]<\/p>\n
The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications to organize and execute an annual conference on dissemination and implementation (D&I) research skills applicable to all NIDCD mission areas, specifically hearing, balance, taste, smell, voice, speech, and language. A cooperative agreement means that an NIDCD Program Official will be designated as Project Coordinator for the conference and will have substantial scientific, programmatic involvement during the award. This funding opportunity aims to support an annual conference focused on building the D&I expertise of investigators conducting or planning on conducting research in NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language. The conference should enhance the ability of attendees to conduct high-quality D&I research in NIDCD mission areas. A permission-to-submit letter is required and should be requested 6 weeks (i.e., October 14, 2024) before the receipt date of November 25, 2024.<\/p>\n
<\/p>\n
For more information, view the funding opportunity\u00a0<\/span>announcement<\/a><\/span>.<\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\"NIDCD - Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" global_colors_info=\"{}\"]<\/p>\n
The National Institute on Deafness and Other Communication Disorders\u2019s (NIDCD) strategic plan includes a focus on dissemination and implementation (D&I) research. D&I is intended to close the gap between research and practice by providing frameworks and tools to understand why evidence-based practices aren\u2019t being used in real world settings and to support people and places in adopting, implementing, and sustaining evidence-based practices. This funding opportunity aims to support early-stage D&I research in NIDCD mission areas of\u00a0hearing, balance, taste, smell, voice, speech, and language. Resulting findings should set a sufficient foundation for a high-quality, D&I focused R01 in NIDCD mission areas. A D&I process model and other core D&I research elements should guide the research goals of the application. A letter of intent is encouraged by September 11, 2024. Applications are due October 11, 2024.<\/p>\n
<\/p>\n
For more information, view the funding opportunity\u00a0<\/span>announcement<\/span><\/a>.<\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\"The American Hearing Research Foundation\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" global_colors_info=\"{}\"]<\/p>\n
![\"\"](\"https:\/\/aro.org\/wp-content\/uploads\/2024\/05\/Screenshot-2024-05-22-161500-300x97.png\")
<\/p>\nThe American Hearing Research Foundation invites researchers to apply for the following grants:<\/p>\n
- \n
- Discovery Grants<\/strong>\u00a0<\/span>\u2013 up to eight one-year awards of up to $50,000 each - for research related to hearing, or hearing and balance disorders of the inner ear. Special consideration in the review process given to these topics: Causes of sudden hearing loss, Meniere\u2019s disease<\/li>\n
- Resident Grants<\/strong>\u00a0<\/span>- up to five $1,000 grants for otolaryngology residents at Chicago universities, Washington University in St. Louis, University of Miami, or Baylor College of Medicine<\/li>\n<\/ul>\n
At its discretion, AHRF may invite applicants of two high-scoring proposals to apply for one of the following: the Birtman Grant, which can provide up to $75,000 in funding, or the Richard G. Muench Chairman Grant, which can provide up to $65,000 in funding.<\/p>\n
Discovery Grant applicants must hold an MD, PhD, AuD, or equivalent degree(s) and be associated with a university or hospital in the United States.<\/p>\n
Important Dates<\/strong><\/p>\n
- \n
- Applications due:\u00a0Thursday, August 15, 2024<\/strong><\/li>\n
- Notification: Last week of November 2024<\/li>\n
- Payment issued: Mid-January 2025<\/li>\n
- Grant period\n
- \n
- Discovery Grants: January 1 \u2013 December 31, 2025<\/li>\n
- Resident Grants: January 1, 2025 \u2013 June 30, 2026<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
For more information, visit\u00a0https:\/\/www.american-hearing.org\/research-grants\/grants-we-offer\/<\/a>\u00a0or contact us at\u00a0<\/span>info@american-hearing.org<\/span><\/a>.<\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\"NIDCD- Training and Center Career Development in Dissemination and Implementation Science for Research in Communications Disorders\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" global_colors_info=\"{}\"]<\/p>\n
NIDCD would like to share a new funding opportunity related training in dissemination and implementation (D&I) science in communication disorders. D&I is intended to close the gap between research and practice by providing frameworks and tools to understand why evidence-based practices aren\u2019t being used in real world settings and to support people and places in adopting, implementing, and sustaining evidence-based practices.<\/p>\n
<\/p>\n
NOT-DC-24-024<\/p>\n
Training and Career Development in Dissemination and Implementation Science for Research in Communication Disorders<\/a><\/span><\/p>\n
<\/p>\n
The purpose of the funding opportunity is\u00a0both (1) to encourage those with expertise in communication disorders to pursue research and training in D&I science,\u00a0and (2) to encourage those with D&I expertise to pursue research and training in the NIDCD mission areas of hearing, balance, taste, smell, voice, speech, and language.<\/p>\n
<\/p>\n
Applications for this initiative must use one of the training and career development funding opportunities listed in the notice with options available across all career stages, including predoctoral students (e.g., F30, F31, FM1), post-doctoral fellows (e.g., F32, K99\/R00, K01), new and junior investigators (e.g., K01, K08, K23, K25), and established investigators (e.g., K18, K24). Likewise, there are institutional funding opportunities aimed at establishing mentoring networks (e.g., R25), providing research experiences (e.g., R25), and enhancing predoctoral and postdoctoral research training (e.g., T32, T35) for D&I research in communication disorders.<\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\"Fondation Pour l\u2019Audition Scientific Prizes - Deadline May 31, 2023\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" disabled=\"on\" global_colors_info=\"{}\"]<\/p>\n
Fondation Pour l\u2019Audition, the French non-profit foundation for Hearing, support talents and honors scientific breakthroughs by awarding with 3 scientific prizes every year.<\/p>\n
Scientific Grand Prize<\/strong><\/p>\n
This prize pays tribute to scientists and clinicians whose work represents a major breakthrough in hearing science, offering new hope to all. Since scientific advances go beyond borders, Fondation Pour l\u2019Audition wants to support experts who are accelerating progress in hearing research, wherever they are \u2013 in France or abroad.<\/p>\n
The Grand Prize is open to active scientists and clinicians (excluding those with emeritus status). Each nomination must be submitted by a peer, who should highlight the candidate\u2019s qualities and achievements. The criteria evaluated include the candidate\u2019s standing and reputation in the scientific and medical community, their expertise, experience and achievements, the quality and excellence of their research, and finally the impact of their work on hearing health.<\/p>\n
The laureate of the Grand Prize is awarded \u20ac65,000 divided in 2 parts : a personal prize of \u20ac40,000 and an optional prize of \u20ac25,000 for a short sabbatical in a research institution in France.<\/p>\n
Early Career Scientific Prizes<\/strong><\/p>\n
Fondation Pour l\u2019Audition Early Career Scientific Prize is awarded annually to two French scientists in recognition of the excellence of their work and its impact on hearing sciences in two categories: clinical research and basic research.<\/p>\n
Each laureate is awarded \u20ac30,000 divided in a personal prize of \u20ac10,000 and a grant for the laboratory's team of the laureate of \u20ac20,000.<\/p>\n
Scientists or clinicians aged up to 45 years old (exceptions can be made on a case-by-case basis depending on maternity and parental leaves<\/em>) and holding a permanent position in a French academic or clinical public research institution are eligible.<\/p>\n
APPLICATION SUBMISSION DEADLINE: May 31, 2023<\/strong><\/p>\n
More info @\u00a0<\/span>https:\/\/www.fondationpourlaudition.org\/scientific-prizes-786-en<\/a><\/p>\n
Contact:\u00a0<\/span><\/a>research@pourlaudition.org<\/a><\/p>\n
<\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\" Meniere's disease funding announcement - Cures Within Reach\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" disabled=\"on\" global_colors_info=\"{}\"]<\/p>\n
OVERVIEW<\/u><\/strong><\/p>\n
This Request for Proposals (RFP) from Cures Within Reach<\/a> (CWR) is seeking both clinical repurposing trials and preclinical repurposing projects to address Meniere\u2019s disease (MD) as well as other vertigo and hearing loss-related diagnoses, such as benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis, to improve patient outcomes. Repurposed therapies must be approved and\/or generally recognized as safe for human use by some regulatory agency<\/strong>, such as the US Food and Drug Administration, European Medicines Agency, Health Canada or Japan\u2019s Pharmaceuticals and Medical Devices Agency, and can include drugs, devices, nutraceuticals, other eligible treatments\/therapies or combination therapies<\/strong>.<\/p>\n
CWR is accepting budgets of up to $100,000 for clinical trials and budgets up to $50,000 for preclinical projects for this RFP, which includes the required 20% institutional match <\/strong>(see Important Funding Information below). Submissions may come from accredited academic, nonprofit and governmental research institutions and\/or health systems significantly involved with medical research located anywhere in the world.<\/p>\n
CWR has a 2-stage submission process, starting with a Letter of Intent (LOI). All submissions for this RFP are via our online grant management platform on ProposalCentral at https:\/\/bit.ly\/submittocwr<\/a> using the Disease Specific Repurposing Research<\/strong> program. For LOI submission instructions and more information about CWR\u2019s funding opportunities, visit https:\/\/bit.ly\/cwrrfps<\/a>.<\/p>\n
LOIs for this RFP will be reviewed, scored and ranked by CWR staff, our external Grant Review Committee and\/or our Science Advisory Board (SAB) members, and the top-rated LOI submissions will be invited to submit a full proposal as the second stage. Principal Investigators (PIs) will be contacted approximately 6-8 weeks following the LOI submission deadline with a decision.<\/p>\n
The LOI submission deadline is 11:59pm U.S. Central Time on March 20, 2023<\/strong>. Contact Clare Thibodeaux, PhD at clare@cureswithinreach.org<\/a> with any questions.<\/p>\n
FULL DESCRIPTION
<\/u><\/strong>Background<\/u><\/strong><\/p>\nThis RFP from CWR is seeking both clinical repurposing trials and preclinical repurposing projects to address Meniere\u2019s disease (MD) as well as other vertigo and hearing loss-related diagnoses, such as benign paroxysmal positional vertigo (BPPV), tinnitus, labyrinthitis and vestibular neuritis. We are interested in generic or proprietary drugs, devices, nutraceuticals or other eligible therapies that could be repurposed to create \u201cnew\u201d treatments to 1) reduce the symptoms, progression or incidence of; 2) restore function lost to; or 3) to reduce or eliminate severe side effects of currently used therapies for MD and\/or other vertigo and hearing loss-related diagnoses, thereby improving patient outcomes and quality of life.<\/p>\n
Repurposed therapies can include drugs, devices, nutraceuticals, other eligible treatments\/therapies or some combination of therapies.<\/strong> Repurposed therapies must be approved and\/or generally recognized as safe for human use by some regulatory agency<\/strong>, such as the US Food and Drug Administration, European Medicines Agency, Health Canada or Japan\u2019s Pharmaceuticals and Medical Devices Agency. Repurposed therapies can be used alone or in combination with other therapies, including the current standard of care.<\/p>\n
Cures Within Reach is circulating this RFP because MD and\/or other vertigo and hearing loss-related diagnoses are currently partially or fully unsolved.\u00a0 An unsolved disease is one in which one or more of the following are true:<\/p>\n
- \n
- There is currently no effective treatment<\/li>\n
- The current treatment is only effective for a portion of the patient population<\/li>\n
- There is a treatment that is effective, but many patients develop resistance to the therapy<\/li>\n
- There is a treatment that is effective for the entire patient population, but the treatment is very expensive, and therefore some patients cannot get access to the treatment<\/li>\n
- There is a treatment that is effective for the entire patient population with significant side effects, and for some patients the negative side effects outweigh the benefits of the treatment<\/li>\n<\/ul>\n
If you have a repurposing idea in MD and\/or other vertigo and hearing loss-related diagnoses that isn't an exact fit for this RFP, or if you have eligibility questions due to budget or other aspects, please contact Clare Thibodeaux, PhD at <\/strong>clare@cureswithinreach.org<\/strong><\/a>\u00a0to discuss fit and\/or submission options<\/strong>.<\/p>\n
Many of our successes in repurposing have come from researchers and clinicians who had ideas that could impact a disease that was outside their normal therapeutic or scientific area. Please submit your repurposing ideas, find colleagues to work with and circulate this RFP to others who you think might be able to submit repurposing research that could provide solutions for an unsolved disease.<\/p>\n
Eligible submissions may:<\/u><\/strong><\/p>\n
- \n
- Repurpose approved and\/or generally recognized as safe drugs, devices, nutraceuticals or other eligible treatments\/therapies<\/li>\n
- Test combination therapies to increase their efficacy, including combining the current disease treatment with a repurposed treatment or combining multiple repurposed therapies<\/li>\n
- Repurpose therapies approved for use in adults into pediatric indications, or vice versa<\/li>\n
- Come from accredited academic, nonprofit and governmental research institutions and\/or health systems significantly involved with medical research located anywhere in the world, where good scientific research and clinical practices can be assured\n
- \n
- Although start-ups, biotechs, pharmaceutical companies and medical device companies are not eligible for this RFP, their collaborators at eligible institutions can apply. Contact Clare Thibodeaux, PhD at clare@cureswithinreach.org<\/a> for more information.<\/li>\n<\/ul>\n<\/li>\n
- Be led either by a previously funded investigator or by an early-stage investigator who has received little or no extramural research funding to date\n
- \n
- PIs who have not received extramural funding previously and\/or who do not currently have their own lab should include a Letter of Support from a funded, senior researcher who will act as a mentor for the proposed research and the investigator<\/li>\n<\/ul>\n<\/li>\n
- Not yet have funding (see Important Funding Information below) or already have funding from another source, when funding from CWR will help improve the chances of success of the project and\/or help speed patient impact<\/li>\n<\/ul>\n
Preferred submissions include<\/u><\/strong>:<\/u><\/p>\n
- \n
- Clinical:<\/u> Our strongest preference is for proof of concept repurposing clinical research trials supported by strong preclinical evidence or clinical observations. We may also consider later stage clinical trials that require additional funding.\n
- \n
- CWR is open to all clinical trial designs (open label, cross-over, dose determination, randomized, blinded, controlled, etc.) that have the opportunity to create a robust and well-defined outcome that will show reproducible clinical impact and\/or generate data that can be leveraged into follow-on funding from other sources and additional clinical trials.<\/li>\n<\/ul>\n<\/li>\n
- Preclinical:<\/u> Our strongest preference is for late-stage preclinical repurposing research projects that are the last step(s) before moving into patients. We will also consider other types of earlier stage preclinical repurposing research that have a translational focus, including drug screening, bioinformatics, genotyping or \u2018omics studies, cell-based assays and animal models.\n
- \n
- Preclinical projects should follow an experimental design and plan that allows for appropriate statistical analyses and reproducibility of the data, resulting in data that can be leveraged into follow-on funding from other sources and additional studies.<\/li>\n
- Preclinical LOI submissions would be strengthened by 1) ideas of how positive results may be used in a clinical setting to create patient impact, and\/or 2) a supporting letter from a clinical collaborator willing to begin clinical trials once positive results are seen.<\/u><\/strong>Important Funding Information<\/u><\/strong><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
- <\/ul>\n
- The project will cost $100,000 to complete, and the maximum funding amount of the RFP is $100,000. This project is eligible for funding from CWR.<\/li>\n
- The project will cost $300,000 to complete, and the maximum funding amount of the RFP is $100,000. The PI has already secured $200,000 in existing funding \/ support. This project is eligible for funding from CWR.<\/li>\n
- The project will cost $300,000 to complete, and the maximum funding amount of the RFP is $100,000. The PI has already secured $0 in existing funding \/ support. This project is not eligible for funding from CWR.<\/li>\n<\/ul>\n
If you have eligibility questions due to the budget or funding amount for your project, please contact Clare Thibodeaux, PhD at <\/strong>clare@cureswithinreach.org<\/strong><\/a>.<\/strong><\/p>\n
CWR is open to working with other funders who share our desire to address MD and\/or other vertigo and hearing loss-related diagnoses and are interested in these near-term repurposing opportunities. We will accept projects that already have funding from another source, when this additional funding from CWR will help improve the chances of success of the project, and therefore increase the chance of patient impact.<\/strong><\/p>\n
Submitting Your LOI and Due Date<\/u><\/strong><\/p>\n
All submissions for this RFP are via CWR\u2019s online grant management platform on ProposalCentral at https:\/\/bit.ly\/submittocwr<\/a> using the Disease Specific Repurposing Research<\/strong> program. If you\u2019re already a ProposalCentral user, log into your existing account to submit. If you don\u2019t already have a<\/p>\n
ProposalCentral account, create a login at https:\/\/proposalcentral.com\/<\/a>.<\/p>\n
The LOI submission deadline is 11:59pm U.S. Central Time on March 20, 2023<\/strong>. Contact Clare Thibodeaux, PhD at clare@cureswithinreach.org<\/a> with any questions \/ issues about the LOI submission deadline.<\/p>\n
For LOI submission instructions and more information about all of CWR\u2019s funding opportunities, visit https:\/\/bit.ly\/cwrrfps<\/a>.<\/p>\n
Review Criteria and Review Process<\/u><\/strong><\/p>\n
Repurposing innovation, feasibility of the research plan, relevance to the patient population, potential clinical impact, \u201cvalue\u201d of the research for the funding and the research team are key ranking criteria for a successful LOI submission. <\/strong>LOIs for this RFP will be reviewed, scored and ranked by CWR staff, our external Grant Review Committee and\/or our Science Advisory Board (SAB) members, and the top-rated LOI submissions will be invited to submit a full proposal. PIs will be contacted approximately 6-8 weeks following the LOI submission deadline with a decision.<\/p>\n
<\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\"Department of Defense Hearing Center of Excellence (HCE)\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" global_colors_info=\"{}\"]<\/p>\n
Funding:\u00a0<\/strong>https:\/\/hearing.health.mil\/Research\/Research-Funding<\/span>
<\/a>National Institute on Deafness and Other Communication\u00a0Disorders (NIDCD)
<\/strong>Homepage:<\/strong>\u00a0<\/span>http:\/\/www.nidcd.nih.gov\/Pages\/default.aspx<\/span>
<\/a>Funding:\u00a0<\/span><\/strong>https:\/\/www.nidcd.nih.gov\/funding<\/a><\/span><\/p>\n[\/et_pb_toggle][et_pb_toggle title=\"NIDCD\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" global_colors_info=\"{}\"]<\/p>\n
![\"\"](\"https:\/\/aro.org\/wp-content\/uploads\/2020\/04\/NIDCD-Header-Logo-300x41.png\")
<\/p>\nNIDCD would like to share two new funding opportunities related to HIV\/AIDS:<\/span><\/p>\n
PAR-20-123<\/strong><\/span>
Advancing HIV\/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)<\/a><\/span><\/p>\nPAR-20-127<\/strong><\/span>
Advancing HIV\/AIDS Research within the Mission<\/span> of the NIDCD (R01 Clinical Trial Optional)<\/a><\/span><\/p>\nThe purpose of these Funding Opportunity Announcements (FOA) are to stimulate HIV\/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). Applications should address high priority HIV\/AIDS research outlined by the NIH Office of AIDS Research (OAR) [https:\/\/www.oar.nih.gov\/hiv-policy-and-research\/research-priorities<\/a><\/span>] in the areas of hearing, balance, taste, smell, voice, speech, and language.<\/span><\/p>\n
[\/et_pb_toggle][et_pb_toggle title=\"Usher Syndrome Society Request for Applications Translational Research Grant\" _builder_version=\"4.27.4\" _module_preset=\"default\" title_text_color=\"#FFFFFF\" title_font=\"|600|||||||\" body_text_color=\"#E6E8E6\" body_link_font=\"|700|||||||\" background_color=\"#0E5688\" disabled=\"on\" global_colors_info=\"{}\"]<\/p>\n
![\"\"](\"https:\/\/aro.org\/wp-content\/uploads\/2021\/07\/usher.jpg\")
Usher Syndrome Society Request for Applications Translational Research Grant <\/a>
<\/strong><\/span><\/p>\nIMPORTANT DATES:<\/u><\/span>
Letter of Intent Due: August 27, 2021 <\/strong><\/span><\/p>\nApplications Due: October 15, 2021 <\/strong><\/span><\/p>\n
Notification of Award: December 1, 2021 <\/strong><\/span><\/p>\n
<\/p>\n
Funds Available: January 1, 2022 <\/strong><\/span><\/p>\n
Please submit grant materials as a single PDF file to<\/span> nancy@ushersyndromesociety.org <\/u><\/span><\/strong><\/p>\n
For questions regarding these instructions, please contact the USS <\/span><\/em>nancy@ushersyndromesociety.org <\/u><\/em><\/span><\/a><\/p>\n
Background: <\/strong>The Usher Syndrome Society (USS) is a non-profit organization that uses the arts, educational events, and collaboration to raise awareness and funding for Usher syndrome (USH) research. USS funds research designed to develop treatments and cures for all forms of Usher syndrome. USS has secured commitments for $500,000 to fund USH research.\u00a0 For more information see: https:\/\/www.ushersyndromesociety.org\/welcome.html <\/u><\/a><\/span><\/p>\n
To fulfill the goal of \u201ctimely and efficient translation\u201d, USS Translational Research Grants are intended to support translation al research on Usher syndrome <\/strong>within the domains of:<\/span><\/p>\n
- \n
CWR is accepting budgets of up to $100,000 for clinical trials and budgets up to $50,000 for preclinical projects for this RFP, which includes the required 20% institutional match. CWR will provide no more than 80% of the total funding amount submitted to CWR, and the PI\u2019s research institution will match at least 20% of the total funding amount submitted to CWR.<\/strong> All funding requests are in US dollars.<\/p>\n
For example, if the total funding amount submitted to CWR is $100,000, CWR will provide 80% or $80,000 and the research institution will provide 20% or $20,000. Submitting an LOI does not commit the PI or the research institution to the 20% institutional match. If a submission is selected to move beyond the LOI stage, we will contact the PI and the research institution about this requirement.<\/p>\n
The 20% institutional match must be real dollars committed to the project and can include indirect costs. The institutional match may come from the research institution itself (including salaries, patient costs, etc.); from government or other public funders; from individuals, foundations or other private funders; from industry (including the dollar value of donated drug); or from any combination of these sources. The CWR portion of the requested total funding amount cannot be used for indirect costs. However, the 20% institutional match may be used for indirect costs.<\/strong><\/p>\n
The total funding amount submitted to CWR must be sole, late or final funding required to accomplish the specific aims listed in the LOI.<\/strong> CWR funding cannot be the first funding raised for a project unless it is also the sole funding needed. The 20% institutional match is not counted as additional funds to be raised. Below are some general examples to help explain:<\/p>\n
- \n
- Clinical:<\/u> Our strongest preference is for proof of concept repurposing clinical research trials supported by strong preclinical evidence or clinical observations. We may also consider later stage clinical trials that require additional funding.\n
- Be led either by a previously funded investigator or by an early-stage investigator who has received little or no extramural research funding to date\n
- Although start-ups, biotechs, pharmaceutical companies and medical device companies are not eligible for this RFP, their collaborators at eligible institutions can apply. Contact Clare Thibodeaux, PhD at clare@cureswithinreach.org<\/a> for more information.<\/li>\n<\/ul>\n<\/li>\n
- Resident Grants<\/strong>\u00a0<\/span>- up to five $1,000 grants for otolaryngology residents at Chicago universities, Washington University in St. Louis, University of Miami, or Baylor College of Medicine<\/li>\n<\/ul>\n
- Discovery Grants<\/strong>\u00a0<\/span>\u2013 up to eight one-year awards of up to $50,000 each - for research related to hearing, or hearing and balance disorders of the inner ear. Special consideration in the review process given to these topics: Causes of sudden hearing loss, Meniere\u2019s disease<\/li>\n
- $100,000 p.a. for two years, up to a total of $200,000<\/li>\n<\/ul>\n<\/ul>\n
- Expanded Discovery Awards\u00a0for\u00a0Central Auditory Processing Disorder<\/u><\/span>\u00a0<\/span><\/li>\n
- $50,000 p.a. for two years, up to a total of $100,000<\/li>\n<\/ul>\n<\/ul>\n
- Focused Discovery Awards\u00a0for\u00a0<\/span>Age-related hearing loss<\/u>,\u00a0<\/span>M\u00e9ni\u00e8re's\u00a0d<\/span>isease<\/u>,<\/span>\u00a0Pain and\/or loudness hyperacusis<\/u>, and\u00a0<\/span>Tinnitus<\/u><\/li>\n
- $50,000 p.a. for two years, up to a total of $100,000<\/li>\n<\/ul>\n<\/ul>\n